Bristol-Myers Squibb Canada’s CLAIRE Patient Support Program
The CLAIRE patient support program is now available to Canadians prescribed Daklinza (daclatasvir), Sovaldi (sofosbuvir), and in some cases ribavirin. The program was designed to help patients seek treatment coverage and provide access to a customized list of services.
It was setup to have a single point of contact for each patient so that they don’t have to navigate through different people each time they call or make an inquiry. One person will take care of them through the program’s duration.
For more information, contact your healthcare provider or the program at: 1-844-HCV-2559 (phone number), 1-844-FAX-2559 (fax number), [email protected] (email address).
Non-Insured Health Benefits Program for First Nations and Inuit
To support First Nations people and Inuit in reaching an overall health status similar to other Canadians, Health Canada’s Non-Insured Health Benefits (NIHB) Program for First Nations and Inuit provides coverage for a limited range of goods and services when they are not insured elsewhere.
Hep C treatments covered by NIHB are labeled as limited use drugs, or drugs effective in specific circumstances. For drugs in this category, specific criteria must be met to be eligible for NIHB coverage.
When specific criteria is met, NIHB covers the following hep C treatments:
- Galexos + pegylated interferon with ribavirin
- Holkira Pak with or without ribavirin *NEW TO NIHB*
- Sovaldi + pegylated interferon with ribavirin
- Sovaldi with ribavirin
Please see the Hepatitis C Treatment Information Project’s Non-Insured Health Benefits Program for First Nations and Inuit page for more information about eligibility or contact Health Canada’s Non-Insured Health Benefits for First Nations and Inuit Program. The program’s number in BC is 604-666-3331 or 1-800-317-7878 (toll-free).
Correctional Services Canada (CSC)
Holkira Pak has also been listed by Correctional Services Canada (CSC). This is great news for a population with an increased chance of having hep C.